Innoviva to Join BofA Securities Health Care Conference 2024

Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced that its Chief Executive Officer, Pavel Raifeld, will present at the BofA Securities Health Care Conference in Las Vegas, NV. The presentation is scheduled for Wednesday, May 15, 2024, at 9:20 a.m. Pacific Daylight Time. Those interested can access a live webcast of the fireside chat in the Investor Relations section on the Company’s website. The webcast will remain available for replay for 90 days following the event.

Innoviva is known for its core royalties portfolio and its significant presence in the critical care and infectious disease sectors through Innoviva Specialty Therapeutics (IST). Additionally, the company has a portfolio of strategic investments in various healthcare assets. A key component of Innoviva’s royalty portfolio involves respiratory products in collaboration with Glaxo Group Limited (GSK). Specifically, Innoviva receives royalties from GSK on sales of products such as RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

Innoviva’s healthcare assets are bolstered by critical care and infectious disease products derived from acquiring companies like Entasis Therapeutics and La Jolla Pharmaceutical Company. Critical products from these acquisitions include XACDURO® (a combination of sulbactam and durlobactam for injection), approved for treating adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by specific strains of Acinetobacter baumannii-calcoaceticus complex. Another notable asset is the investigational drug zoliflodacin, which is currently under development for treating uncomplicated gonorrhea.

Moreover, Innoviva owns GIAPREZA® (angiotensin II), which is approved to elevate blood pressure in adults experiencing septic or other forms of distributive shock. The company also markets XERAVA® (eravacycline), an antibiotic approved for treating complicated intra-abdominal infections in adults.

The trademarks ANORO®, RELVAR®, BREO®, and TRELEGY® are owned by the GSK group of companies.

By maintaining a diversified portfolio and strategic investments, Innoviva continues to solidify its position in the healthcare sector, particularly in the areas of respiratory, critical care, and infectious diseases. The company’s forward-thinking approach and robust partnerships enable it to innovate and expand its market presence continually.